<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shuman, Jill</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Trainer, Peter J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ATL1103 Effective in Reducing IGF-1 Levels in Patients With Acromegaly</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-18 15:35:55</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Acromegaly is caused by an overproduction of growth hormone, and subsequently, insulin-like growth factor-I. ALT1103 is second-generation drug that reduces expression of the growth hormone receptor. In a phase 2 trial, patients with acromegaly who received 400 mg of ALT1103 showed a significant reduction in insulin-like growth factor-I at 14 weeks.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>